LFB BIOMANUFACTURING, your one-stop CDMO partner

At LFB Biomanufacturing, we provide end‑to‑end CDMO services for therapeutic antibodies and recombinant proteins — starting from cell line development all the way through GMP manufacturing of drug substance.

Our facility leverages flexible and modern technologies, with nearly all systems being disposable, to adapt quickly to your needs while keeping costs under control.

Backed by the pharmaceutical expertise of the LFB Group and fully inspected and approved by both the FDA and ANSM, we combine regulatory strength with operational flexibility to deliver reliable, high‑quality bioproduction.

At LFB Biomanufacturing, we build your molecule’s production backbone through expert cell line development — from expression vector design to stable clone selection and GMP‑ready cell banks. Using either CHO or our proprietary EMABling® platforms, we ensure high quality, scalability and customised solutions.

From optimizing upstream cell culture and serum-free media to refining purification and analytics, we prepare your process for GMP scale-up. Using statistical design methods and structured quality planning, and carrying out pilot-scale batches up to 200 L, we ensure robustness, reproducibility and a smooth tech transfer toward manufacturing.

From master and working cell banks to validated large-scale batches, we deliver full GMP manufacturing: media and buffer preparation, analytic method validation, quality control, stability studies, and regulatory support — all under rigorously certified conditions.

LFB BIOMANUFACTURING, one of the key entities in the LFB group’s bioproduction activities, operates the Alès (Gard department) industrial site specialising in the manufacture of recombinant medicinal products by cell culture, and of recombinant proteins and monoclonal antibodies in particular.